{
  "docId": "019dd923-622c-750b-8b9a-8c03a48e7d6f",
  "docSlug": "86e21d9d1e23",
  "documentTitle": "PMV Pharmaceuticals (PMVP)",
  "authorId": "60_Wolfpack_Research",
  "authorName": "Wolfpack Research",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2022-05-19 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 3,
  "pageCount": 19,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "villain_critique",
  "function": "name_villain",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses a combination of narrative critique and a scientific diagram to frame the company's technology as potentially ineffective.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "process_diagram",
    "screenshot",
    "footnote"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-8c03a48e7d6f/3",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-8c03a48e7d6f",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-8c03a48e7d6f.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-8c03a48e7d6f#slide-3",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "PMV’s website and investor communications are filled with general p53 information designed to intrigue retail investors but lacks current data and hard science.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-70f9-71ae-a678-e26baf8879ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.1,
        "y": 0.75
      },
      "kind": "diagram",
      "text": "Biology of p53 Reactivation flow: Induced conversion -> Evidenced by p53-dependent activity -> Biological Consequences",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "244228a9-0fff-43b3-8460-b50c192e0cc3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.8,
        "x": 0.1,
        "y": 0.55
      },
      "kind": "image",
      "text": "Diagram showing Wild-type p53, Mutant p53 Y220C, and Mutant p53 Y220C with PC14586",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fd7b465e-7ffd-4c4a-a5ba-eb3d2cabebeb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.1,
        "y": 0.35
      },
      "kind": "paragraph",
      "text": "Even though PMV has several different drugs in the beginning stages of development, its hopes are currently riding on one drug, PC 14586, which has advanced through the preclinical stages and into Phase I.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3908c290-61f9-4c18-b199-4b10333bc32c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.1,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "One of PMV's co-founders, Dr. Arnold Levine, was part of the initial discovery of the p53 protein in 1979. While Dr. Levine has made great contributions to medicine in his 82 years, the company he started appears now to emphasize Levine's past accomplishments over new hard data. PMV's website and investor communications are filled with general p53 information designed to intrigue retail investors but lacks current data and hard science.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "55c38126-b340-4aec-ad9c-e8af9f9602c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.1,
        "y": 0.42
      },
      "kind": "paragraph",
      "text": "PMV designed PC14586 to stabilize the p53 Y220C point mutation in which tyrosine (T) is substituted by cysteine (C) at amino acid 220 of the protein. This single amino acid change creates a small crevice in the p53 protein, making it thermally unstable and unable to effectively interact with DNA. PC14586 targets this crevice with a small molecule meant to restore function to p53 Y220C.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c2d05bc6-049f-495b-a85e-c9426520c758",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.1,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "4 PMVP, 10-K, 11, 3/1/2022",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "723bccf7-e0d2-43ee-a892-f520b59873f5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.4,
        "x": 0.3,
        "y": 0.86
      },
      "kind": "source-note",
      "text": "Source: PMV Pharma's Investor Presentation (Jan 2022)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c8496afe-4fb4-4f69-b3c8-aac4f4446687",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.8,
        "x": 0.1,
        "y": 0.18
      },
      "kind": "title",
      "text": "PMV's Leading Drug Candidate Attempts to Restore Proper Cell Function to the p53 Protein",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ba36bedd-f69c-4891-8c2f-e226bc003a71",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.1,
        "y": 0.1
      },
      "kind": "title",
      "text": "Analysis: Red Flags from PMV's Preclinical and Early Clinical Results Indicate That PMV's Leading Drug Will Fail Due to Lack of Potency and Other Deficiencies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "138dc5b0-2a85-47a0-bc85-a3eae916925e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 12,
      "from": 3,
      "beatId": "f89a3578-3b10-48a0-a0dc-890f21967937",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Monster",
      "beatSlug": "overcoming-monster-the-monster",
      "evidence": "The document exposes contradictions and concerns regarding PMV Pharma's drug candidate.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Hook",
      "parentBeatSlug": "hook"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}